Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioNova Acquires Rights to CD74 Candidate from Sutro in $204 Million Deal

publication date: Oct 12, 2021

Shanghai BioNova Pharma acquired an option for China rights to a CD74 antibody drug candidate for hematologic cancers from South San Francisco's Sutro Biopharma in a $204 million agreement. BioNova will make a $4 million payment for the option, and it will pay up to $200 million to exercise the option and make milestone payments. It will develop STRO-001 to treat non-Hodgkin's lymphoma, multiple myeloma and leukemia. Sutro will also receive tiered, double-digit royalties. More details....

Stock Symbol: (NSDQ: STRO)

Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital